GlassScriptPhysician profile
Saad Ahmed
NPI 1336619550
$2,770.64
in general payments reported to CMS, 2019-2025
19 companies · $745 in 2025
The $745 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.38 · 2020: $143 · 2021: $288 · 2022: $215 · 2023: $568 · 2024: $755 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $830.27 | 2022-2025 | Rocklatan, Simbrinza, Rhopressa |
| Bausch & Lomb Americas INC. | $378.87 | 2023-2025 | Xiidra, Miebo, Infuse |
| Johnson & Johnson Vision Care, INC. | $343.76 | 2021-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $219.62 | 2019-2023 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $196.01 | 2019-2021 | |
| Sight Sciences, INC. | $147.49 | 2025 | Tearcare System |
| Allergan, INC. | $117.91 | 2021 | |
| Biotissue Holdings INC. | $107.13 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $81.95 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $60.00 | 2022-2023 | |
| Thea Pharma INC. | $45.16 | 2025 | Iyuzeh |
| Dompe US, INC. | $39.72 | 2024-2025 | Oxervate |
| Glaukos Corporation | $38.40 | 2021 | |
| Coopervision INC. | $37.58 | 2022-2025 | Clariti Contact Lens |
| Oyster Point Pharma, INC. | $34.12 | 2023 | Tyrvaya |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.50 | 2024-2025 | Acthar |
| Pfizer INC. | $24.02 | 2023 | |
| Amgen INC. | $22.14 | 2025 | Tepezza |
| Abbvie INC. | $13.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.